Agilent CDx Symposium 2026

Hilton Santa Barbara Beachfront Resort
April 8th, 2026

Precision Unlocked: Innovating CDx Development and AI-Powered Diagnostics

Please join Agilent and leading industry experts for our 4th Annual CDx Symposium in Santa Barbara, CA. As precision medicine continues to move forward at record speed, this symposium will address several hot topics impacting targeted therapies and the evolution of companion diagnostics.

Early translation and biomarker discovery roundtable
New frontiers in CDx development
AI-powered CDx and digital pathology case study
Patient perspectives

2025 Symposium Highlights

View 2025 agenda

CDx in the News

New

Celebrating the 10th Anniversary of its PD-L1 CDx, Agilent Sets Sights on Next-Gen Diagnostic Tools

October marks the 10-year anniversary of the US Food and Drug Administration’s approval of the first companion diagnostic test for a PD-L1 inhibitor. A decade after the initial approval of Agilent's PD-L1 IHC 22C3 pharmDx, IHC assays continue to be the mainstay in identifying patients likely to respond to targeted therapies and are critical to the success of precision medicine.

New

Lunit and Agilent Technologies Announce Collaboration to Enhance Development of Companion Diagnostic Solutions Powered with AI for Precision Medicine

The collaboration will leverage Lunit’s AI technology and Agilent’s expertise in tissue-based companion diagnostics to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development.

Agilent MMR IHC Panel pharmDx (Dako Omnis) Receives FDA Approval as a Companion Diagnostic Test for Colorectal Cancer

This test aids in identifying mismatch repair deficient (dMMR) colorectal cancer (CRC) patients who are eligible for treatment with Bristol Myers Squibb’s Opdivo® (nivolumab) alone or Opdivo (nivolumab) in combination with Yervoy® (ipilimumab).

Leading the Way in Companion Diagnostics

Never has there been more information to enable a patient’s fight against cancer, but how does one select the right treatment? This is how Companion diagnostics (CDx) fit with precision medicine.

The Future of Cancer Care, According to the Experts

A panel of experts, including Gulzar Sandhu, Chief Business Officer of Companion Diagnostics at Agilent, shares opinions on the future of oncology and breakthroughs in cancer treatment.

Top Trends Driving Priorities for Companion Diagnostics Development

Companion diagnostics (CDx) have become an essential tool to identify patients that benefit from targeted therapies in the precision medicine landscape. Recent shifts in the pharma pipeline and diagnostic strategies as well as regulatory requirements are transforming the current CDx development paradigm and prompting pharma companies to think differently about drug development.

Unpacking the Complexities of Companion Diagnostics for Cell and Gene Therapies

Companies like Agilent are already seeing a growing demand for diagnostic support related to CGT trials and commercialization, with therapy areas expanding from oncology and rare diseases to more common conditions like congestive heart failure with a genetic component and neurological conditions such as Parkinson's disease.

Join Agilent at ASCO 2025

Accelerate your CDx development program by leveraging our broad technical expertise, global infrastructure and decades of proven experience. Visit us in Booth 36076 to discuss our CDx capabilities.

AI-integrated Companion Diagnostics

Douglas Clark, Chief Pathologist for Companion Diagnostics at Agilent, discusses how enhanced companion diagnostics are shaping the future of pathology – and how their adoption will help advance patient care.

Improving Productivity in Digital Pathology Using AI

Powerful collaborations, like the one between Agilent, Hamamatsu, PathAI, Proscia, and Visiopharm revolutionize digital pathology by integrating cutting-edge technologies into a seamless, end-to-end solution

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications

PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR1

Agilent Companion Diagnostic Assay PD-L1 IHC 28-8 pharmDx Receives European IVDR Certification

Announcing the issuing of a Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for PD-L1 IHC 28-8 pharmDx (Code SK005)

Agilent Unveils Biopharma CDx Services Lab to Accelerate Precision Medicine

New CLIA-certified lab ensures seamless transition from early assay development and testing to full companion diagnostics commercialization

Agilent Nabs FDA Approval for Soft Tissue Cancer CDx

The MAGE-A4 IHC 1F9 PharmDx assay is used to guide the treatment of synovial sarcoma patients with Adaptimmune Therapeutics' newly approved treatment Tecelra.

Agilent Receives FDA Approval for MAGE-A4 IHC 1F9 pharmDx as a Diagnostic Tool for Use with Newly Approved TCR T-Cell Therapy

MAGE-A4 IHC 1F9 pharmDx is indicated as an aid in identifying patients with synovial sarcoma for whom TECELRA®, a MAGE-A4-directed engineered T-Cell Receptor (TCR) therapy is being considered

Complex Therapies, Complex Diagnostics

Learn about Agilent's efforts in creating companion diagnostics for innovative drug classes such as Antibody-Drug Conjugates (ADCs), bi- and tri-specific antibody therapies and immuno-oncology combination therapies.

Inside Precision Medicine: New Frontiers in CDx Development

In the latest Inside Precision Medicine, CDx VP/GM Paul Beresford discusses industry-leading innovations in early-stage diagnostics, digitalization and machine learning.

Opportunities & Challenges of Digital Pathology Adoption in CDx Development

In this new podcast by Fierce Pharma, two of our industry experts, Grace Lee, AVP of CDx Global Regulatory Affairs and Douglas P. Clark, MD, Chief Pathologist of CDx explore the vast opportunities and challenges associated with implementing AI and digitalpathology into CDx development.

Transcenta Announces Collaboration with Agilent to Develop a Claudin 18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial

Agilent and Transcenta presented the early results of the Claudin 18.2 IHC 14G11 pharmDx assay at AACR Annual Meeting.

Agilent Announces Collaboration with Incyte to Develop Advanced Companion Diagnostics in Hematology and Oncology

The partnership will leverage Agilent's expertise in assay development with Incyte's innovation in drug discovery.

Addressing pharma's evolving needs for CDx development

In this podcast by Fierce Pharma, CDx VP/GM Paul Beresford and Pathology VP/GM Lou Welebob discuss the advantages of pharma partnerships and look ahead to the future of CDx.

Tissue-Based Multiplex Biomarker Assays and Companion Diagnostics

From the Journal of Precision Medicine, Agilent CDx gives an overview of multi-plexing, a technology Agilent uses to develop complex companion diagnostics.

Editorial Article: Tools to advance precision oncology

Dr. John Palma, Global Head of Medical Affairs at Agilent, offers insights into the technologies driving the field of precision oncology

Agilent Aims to Ramp up Early-Stage CDx Development Deals

CDx VP/GM Paul Beresford on Agilent's steps toward becoming a one-stop shop for early-stage precision oncology research, including AI partnerships and Agilent's upcoming Biopharma CDx Services Lab.

Visit the Agilent Newsroom for all press releases and media coverage.

Visit Agilent CDx News & Events

For more information about Companion Diagnostics at Agilent, visit our CDx home

Visit CDx home

D0127644_1.00